Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, Schmidinger M.

Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413.

PMID:
24641566
[PubMed - in process]
2.

Axitinib for the treatment of advanced renal cell carcinoma.

Akaza H, Fukuyama T.

Expert Opin Pharmacother. 2014 Feb;15(2):283-97. doi: 10.1517/14656566.2014.868436. Epub 2013 Dec 13. Review.

PMID:
24328549
[PubMed - indexed for MEDLINE]
3.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ.

Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Erratum in: Lancet. 2012 Nov 24;380(9856):1818.

PMID:
22056247
[PubMed - indexed for MEDLINE]
4.

Axitinib for the management of metastatic renal cell carcinoma.

Escudier B, Gore M.

Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000. Review.

PMID:
21679004
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.

Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H.

Jpn J Clin Oncol. 2013 Jun;43(6):616-28. doi: 10.1093/jjco/hyt054. Epub 2013 Apr 28.

PMID:
23630366
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Optimal management of metastatic renal cell carcinoma: current status.

Escudier B, Albiges L, Sonpavde G.

Drugs. 2013 Apr;73(5):427-38. doi: 10.1007/s40265-013-0043-1. Review.

PMID:
23572408
[PubMed - indexed for MEDLINE]
7.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

PMID:
21952069
[PubMed - indexed for MEDLINE]
8.

Axitinib in Metastatic Renal Cell Carcinoma.

Mittal K, Wood LS, Rini BI.

Biol Ther. 2012 Oct 16;2:5. eCollection 2012. Review.

PMID:
24392298
[PubMed]
Free PMC Article
9.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.

Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.

PMID:
24823696
[PubMed - in process]
Free PMC Article
10.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.

J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3.

PMID:
19652060
[PubMed - indexed for MEDLINE]
Free Article
11.

Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.

Larkin J, Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M.

Am J Clin Oncol. 2014 Aug;37(4):397-403. doi: 10.1097/COC.0b013e31827b45f9.

PMID:
23357974
[PubMed - in process]
12.

Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report.

Yuki H, Kamai T, Kubota K, Abe H, Nishihara D, Mizuno T, Masuda A, Betsunoh H, Yashi M, Fukabori Y, Yoshida K.

Onco Targets Ther. 2014 Feb 15;7:289-95. doi: 10.2147/OTT.S58089. eCollection 2014.

PMID:
24627641
[PubMed]
Free PMC Article
13.

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.

Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ.

Target Oncol. 2014 Mar 5. [Epub ahead of print]

PMID:
24595903
[PubMed - as supplied by publisher]
14.

Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.

Carmichael C, Lau C, Josephson DY, Pal SK.

Clin Adv Hematol Oncol. 2012 May;10(5):307-14. Review.

PMID:
22706540
[PubMed - in process]
15.

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

Dranitsaris G, Schmitz S, Broom RJ.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1917-26. doi: 10.1007/s00432-013-1510-5. Epub 2013 Sep 14. Review.

PMID:
24037486
[PubMed - indexed for MEDLINE]
16.

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.

Grünwald V, Merseburger AS.

Onco Targets Ther. 2012;5:111-7. doi: 10.2147/OTT.S23273. Epub 2012 Jun 18.

PMID:
22787405
[PubMed]
Free PMC Article
17.

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.

Cohen RB, Oudard S.

Invest New Drugs. 2012 Oct;30(5):2066-79. doi: 10.1007/s10637-012-9796-8. Epub 2012 Feb 12. Review.

PMID:
22327313
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Axitinib: in advanced, treatment-experienced renal cell carcinoma.

Yang LP, McKeage K.

Drugs. 2012 Dec 24;72(18):2375-84. doi: 10.2165/11209230-000000000-00000.

PMID:
23190347
[PubMed - indexed for MEDLINE]
19.

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G.

Pharmgenomics Pers Med. 2014 Mar 27;7:107-16. doi: 10.2147/PGPM.S37098. eCollection 2014. Review.

PMID:
24715765
[PubMed]
Free PMC Article
20.

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE.

J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9.

PMID:
24019545
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk